Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CD22 CAR-T cells (Shanxi Province Cancer Hospital)
- Development stage
- Phase 2
- Lead developer
- Shanxi Cancer Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19-CD22 CAR-T cells (Shanxi Province Cancer Hospital) is an investigational autologous dual-target chimeric antigen receptor (CAR) T-cell therapy. Developed by the Shanxi Province Cancer Hospital, this therapy is designed to treat relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The patient's own T cells are genetically modified to express CARs that simultaneously recognize CD19 and CD22 antigens on the surface of malignant B cells. This dual-targeting strategy is intended to mitigate the risk of 'antigen escape,' a common mechanism of resistance where cancer cells lose a single target antigen to evade the immune system. The therapy is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with relapsed or refractory acute B lymphocytic leukemia.
- Other names
- CD19-CD22 CAR-T cellsCD-19-CD22 CAR-T cellsCD 19-CD22 CAR-T cellsCD19/CD22 dual-target CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD19-CD22 CAR-T cells (Shanxi Province Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CD22 CAR-T cells (Shanxi Province Cancer Hospital).